Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in Amyotrophic Lateral Sclerosis
NCT03693781Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Apr 2019
- Primary completion
- Apr 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of colchicine in amyotrophic lateral sclerosis (ALS), sponsored by Azienda Ospedaliera Universitaria Policlinico. Started Apr 2019; status: completed.
02
Drugs
colchicine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03693781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693781.